Market news

On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 […]

United Therapeutics (UTHR) stock and Sagimet Biosciences (SGMT) stock slip as Goldman Sachs issued Sell ratings on the companies. Read more here.

Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.33, according t

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here).H.C. Wainwright 28th Annual Global Investment Conf

Sagimet Biosciences (SGMT) said Tuesday that it expects to begin enrolling patients in Q4 for the US

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on Aug

Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executive

Sagimet Biosciences (SGMT) stock rises as the FDA clears a Phase 3 clinical trial for the company's acne candidate, denifanstat. Read more here.

Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026FOSTER CITY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application and issued a “Study M

Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.

Sagimet Biosciences (SGMT) is making "good progress" in advancing denifanstat as a treatment for mod

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured equity financing with gross proceeds of $175.0 million in April 2026 Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to severe

FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here). About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company

Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple. On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focused Russell 2000 Index, as part of the Russell Indexes reconstitution for 2026. The June index reconstitution […]